Work

No Increase in Malignancy Risk with Cladribine Tablets in Patients with Relapsing Multiple Sclerosis

Year: 2018

Type: article

Source: Multiple Sclerosis and Related Disorders

DOI: 10.1016/j.msard.2018.10.094

Authors: A. Galazka, A. Nolting, S. Cook, T. Leist, G. Comi, X. Montalban, C. Hicking, F. Dangond

Institutions: Merck Serono S.A. (Switzerland), Merck KGaA, Darmstadt (Germany), Rutgers, The State University of New Jersey, Rutgers New Jersey Medical School, Thomas Jefferson University, Vita-Salute San Raffaele University, IRCCS Ospedale San Raffaele, St. Michael's Hospital, University of Toronto, Merck Healthcare KGaA, Darmstadt (Germany)

Language: English

Topic: Multiple Sclerosis Research Studies

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2904916284

FWCI:

Cites:

Cited by:

Related to: 10